Drugs / Caffeic acid
Caffeic acid
also known as
2-PROPENOIC ACID, 3-(3,4-DIHYDROXYPHENYL)-, (2E)- · NSC-57197 · NSC-623438 · trans-3,4-dihydroxycinnamic acid · Trans-caffeate · Trans-caffeic acid
Small molecule targets KDM4C via inhibition
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 33 trials | ||||||
| Phase 3 | NCT04648917 | May 2019 → May 2021 | esophageal cancer | The First Affiliated Hospital of Henan University of Science and Technology | Unknown | No outcome recorded |
| Phase 3 | NCT03070262 | Jan 2017 → Dec 2020 | esophageal cancer | The First Affiliated Hospital of Henan University of Science and Technology | Unknown | No outcome recorded |
| Phase 3 | NCT02351622 | Sep 2012 → Dec 2013 | autoimmune thrombocytopenia | Shandong University | Completed | No outcome recorded |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT02556814 | Sep 2015 → Mar 2018 | thrombocytopenia due to immune destruction | Shandong University | Completed | Met primary |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Caffeic acid | “caffeic acid, 300mg, tid, po” NCT03070262 ↗ |
| Known as | 2-PROPENOIC ACID, 3-(3,4-DIHYDROXYPHENYL)-, (2E)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL145 ↗ |
| Known as | NSC-57197 | ChEMBL registry synonym — accepted as the source's own label CHEMBL145 ↗ |
| Known as | NSC-623438 | ChEMBL registry synonym — accepted as the source's own label CHEMBL145 ↗ |
| Known as | trans-3,4-dihydroxycinnamic acid | “The efficacy of cancer treatments is often limited and associated with substantial toxicity. Appropriate combination of drug targeting specific mechanisms may regulate...” PMID 28230778 ↗ Feb 2017 |
| Known as | Trans-caffeate | ChEMBL registry synonym — accepted as the source's own label CHEMBL145 ↗ |
| Known as | Trans-caffeic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL145 ↗ |
| Action | Inhibit | “Caffeic acid can target inhibit GASC1 (gene amplified in squamous cell carcinoma 1, also known as KDM4C and JMJD2C) expression” NCT03070262 ↗ |
| Modality | Small molecule | — CHEMBL145 ↗ |
| Route | Oral | “Oral administration of caffeic acid tablet 0.3g three times per day for 1 year” NCT02351622 ↗ |
| Target | KDM4C | “Caffeic acid can target inhibit GASC1 (gene amplified in squamous cell carcinoma 1, also known as KDM4C and JMJD2C) expression” NCT03070262 ↗ |